Cynosure Group LLC Sells 359 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Cynosure Group LLC reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,630 shares of the company’s stock after selling 359 shares during the quarter. Cynosure Group LLC’s holdings in Krystal Biotech were worth $569,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth approximately $40,000. Avanza Fonder AB acquired a new stake in shares of Krystal Biotech in the 4th quarter valued at $119,000. KBC Group NV increased its stake in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after buying an additional 433 shares in the last quarter. Finally, US Bancorp DE raised its holdings in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after buying an additional 82 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on KRYS shares. HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital increased their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Citigroup boosted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and an average target price of $220.00.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Trading Down 3.2 %

NASDAQ KRYS opened at $174.58 on Wednesday. The firm has a market capitalization of $5.03 billion, a PE ratio of 58.39 and a beta of 0.87. The business’s 50-day moving average price is $171.92 and its two-hundred day moving average price is $173.26. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period in the prior year, the business posted $0.30 earnings per share. The firm’s revenue was up 116.4% on a year-over-year basis. As a group, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).